Iterum Therapeutics PLC

NASDAQ ITRM

Data sourced from iex and EODHD
Download Data

Iterum Therapeutics PLC Enterprise Value to EBITDA (EV/EBITDA) on June 03, 2024: -0.59

Iterum Therapeutics PLC Enterprise Value to EBITDA (EV/EBITDA) is -0.59 on June 03, 2024, a NA change year over year. The EV/EBITDA ratio compares a company's enterprise value to its EBITDA. It provides insight into the company's valuation relative to its earnings and is commonly used in comparing the relative value of different companies within an industry. A lower ratio suggests a potentially more favorable valuation.
  • Iterum Therapeutics PLC 52-week high Enterprise Value to EBITDA (EV/EBITDA) is 0.00 on February 29, 2024, which is 100.78% above the current Enterprise Value to EBITDA (EV/EBITDA).
  • Iterum Therapeutics PLC 52-week low Enterprise Value to EBITDA (EV/EBITDA) is -0.63 on May 13, 2024, which is -5.75% below the current Enterprise Value to EBITDA (EV/EBITDA).
  • Iterum Therapeutics PLC average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is -0.34.
NASDAQ: ITRM

Iterum Therapeutics PLC

CEO Mr. Corey N. Fishman
IPO Date May 25, 2018
Location Ireland
Headquarters Fitzwilliam Court, Dublin, Ireland, 2
Employees 14
Sector Healthcare
Industry Biotechnology
Description

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Similar companies

HOTH

Hoth Therapeutics Inc

USD 1.17

0.00%

StockViz Staff

September 8, 2024

Any question? Send us an email